

Organism	Number of Isolates*	Ampicillin	Amoxicillin/clavulanate	Piperacillin/tazobactam	Cefazolin**	Cefoxitin	Cefepime	Ceftazidime	Ceftriaxone	Meropenem	Ciprofloxacin	Levofloxacin	Gentamicin#	Tobramycin	Tetracycline (Doxycycline)	Trimethoprim/sulfamethoxazole (Bactrim)	Nitrofurantoin	Clindamycin	Erythromycin	Azithromycin	Ertapenem	Oxacillin†	Penicillin	Vancomycin	Linezolid	
ESCHERICHIA COLI (includes ESBL)	706	48	81	96	84	82	90	90	90	100	66	66	92	92	74	74	95									
ESCHERICHIA COLI - ESBL	73	0	54	92	0	57	0	0	0	100	18	18	88	73	40	47	93									
PROTEUS MIRABILIS	242	83	100	100	99	94	100	100	100	100	62	64	98	99	0	72	0									
KLEBSIELLA PNEUMONIAE	181	0	96	97	97	93	99	99	99	98	95	96	99	98	85	92	51									
ENTEROBACTER CLOACAE COMPLEX	42	0	0	84	0	0	98	79	71	98	100	100	95	93	87	95	34									
PSEUDOMONAS AERUGINOSA	107	NI‡	NI‡	89	NI‡	NI‡	93	86	NI‡	88	83	77	87	96	NI‡	NI‡	NI‡									
ENTEROCOCCUS SP., VSE	107	88									52	54			27	100	88							100	100	
STAPH. AUREUS, MSSA	43										49	49	100		86	98	100	90	62			100	0	100	100	
STAPH. AUREUS, MRSA	37										14	11	100		95	97	97	70	30			0	0	97	100	
HAEM INFLUENZAE COMM WIDE	183	59							100		99	100			100	63				100						
STREP PNEUMONIAE COMM WIDE	113								94			99			75	85		77	58	58		96§	100	100		

* Note: isolates from all sources; urine, blood, respiratory, wound, etc.

** For uncomplicated UTIs, Cefazolin MIC results less than or equal to 16 mcg/ml predict susceptibility of the following oral cephalosporins: cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, and cephalexin.

† Oxacillin-susceptible Staph are also susceptible to other penicillinase-resistant penicillins, betalactam/betalactamase inhibitor combinations, cepheems, and carbapenems FDA-approved to treat Staph infections.

Gentamicin may be used in combination with other drugs against Staph isolates.

§ 96% were in the intermediate or susceptible range, indicating many could be treated for pneumonia with appropriate dosing of an IV penicillin.

¶ NI = drug not active.

The percentages in red are greater than or equal to 80% susceptibility, potentially useful for empiric therapy.